Roche Keeps Eye On The Science As Asia Innovation Emerges
Executive Summary
Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.
You may also be interested in...
Need For Partnering Won’t Change But Shape Might - BioJapan
While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.
Roche Ups Outlook, Sees Spark Buy By Year-End
Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.